Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapy
(2015) Expert Review of Anticancer Therapy — Vol. 15, n° 1, p. 121-128 (2015)
Files
No attached file found for this publication.
Details
- Authors
- Abstract
- In recent years, the treatment landscape in advanced non-squamous non-small-cell lung cancer (nsNSCLC) has changed. New therapies (e.g., bevacizumab indicated in first line) have become available and other therapies (e.g., pemetrexed in first line and second line) moved into earlier lines in the treatment paradigm. While there has been an expansion of the available treatment options, it is still a key research question which therapy sequence results in the best survival outcomes for patients with nsNSCLC.
- Affiliations
Citations
Walzer, S., Chouaid, C., Lister, J., Gultyaev, D., Vergnenegre, A., de Marinis, F., Meng, J., de Castro Carpeno, J., Crott, R., Kleman, M., & Ngoh, C. (2015). Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapy. Expert Review of Anticancer Therapy, 15(1), 121-128. https://doi.org/10.1586/14737140.2015.961428 (Original work published 2015)